Clinical trials: Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- Condition Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- Funder type Industry (pharma, biotech, devices)
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA).
- Trial name
- NCT07033481
- Testing
- Neflamapimod
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- EIP Pharma Inc